MSB 12.1% 55.5¢ mesoblast limited

Stem cells ramping up.., page-69

  1. 5,344 Posts.
    lightbulb Created with Sketch. 953
    The J P Morgan healthcare conference may be over bit that doesn't mean the deal making is over , often deals that took shape at the meeting materialise later in the year ,and some recent buzz puts Pfizer and Biogen and the centre of potential deals ...Pfizer is reportedly eyeing a buyout of cardiovascular player Amarin ..Meanwhile Biogen could be another player if JPM executives are any indications , " The big Biotech would love to get it's hands on something a bit larger with multiple phase 3 assets " management said, as quoted by Mizuho analyst Salim Syed who noted the company has $ 13 bill.worth of finance capacity ..That kind-of deal would invoke a change of business development strategy for Biogen which has traditionally done early stage deals ..........


    The long awaited M&A boom will hit Biopharma in 2019 despite the constant worries Prognosticators predict ....As Col would state " just saying "
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
0.060(12.1%)
Mkt cap ! $633.0M
Open High Low Value Volume
50.0¢ 59.0¢ 48.5¢ $16.88M 30.80M

Buyers (Bids)

No. Vol. Price($)
4 62700 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.0¢ 40000 1
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
55.5¢
  Change
0.060 ( 15.7 %)
Open High Low Volume
50.5¢ 59.0¢ 48.5¢ 11524458
Last updated 16.02pm 29/03/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.